Search
recombinant factor Xa (Andexxa)
Indications:
- life-threatening or uncontrolled bleeding due to ovedose of factor Xa inhibitor (FDA-approved May 2018)
Adverse effects:
- most common:
- urinary tract infections
- pneumonia
* boxed warning
- thromboembolism
- ischemia
- cardiac arrest
Mechanism of action:
- recombinant, inactivated factor Xa
- median decrease in anti-factor Xa activity from baseline
- 90% for rivaroxaban, 93% for apixaban
General
coagulation factor Xa
antidote
References
- Wendling P
FDA Approves First Factor Xa Inhibitor Antidote, Andexxa.
Medscape - May 04, 2018.
https://www.medscape.com/viewarticle/896182